Arcutis Biotherapeutics, Inc. · NASDAQ:ARQT
Arcutis Biotherapeutics — Q1 2026 Earnings Presentation
22 slides from Arcutis Biotherapeutics's earnings presentation, May 6, 2026
Slide 1: 1st Quarter 2026 Financial Results
1 Quarter 2026 st Financial Results May 6, 2026
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation and the accompanying oral presentation contain manufacturing capabilities and strategy; current and future the accompanying oral presentation are made pursuant to the forward-looking statements within the meaning of Section 27A of agreements with third parties in
Slide 3: Today's Speakers
Today’s Speakers Frank Watanabe Todd Edwards Patrick Burnett, Latha Vairavan President & CEO Chief Commercial MD, PhD, FAAD Chief Financial Officer Officer Chief Medical Officer ©Copyright 2026. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 3
Slide 4: Speakers & Agenda: Business Review
Speakers & Agenda Business Review Frank Watanabe President & CEO ©Copyright 2026. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 4
Slide 5: Our Strategy to Sustain Near- and Long-term Growth
Our Strategy to Sustain Near- and Long-term Growth Grow current Expand ZORYVE Build our pipeline ZORYVE business into new markets • Submitted sNDA for • Nearing full enrollment for • Initiated Ph 1a/1b trial for ZORYVE® (roflumilast) Ph 2 vitiligo POC trial ARQ-234 cream 0.05% in AD • Continue to en
Slide 6: Speakers & Agenda: Commercial Update
Speakers & Agenda Commercial Update Todd Edwards Chief Commercial Officer ©Copyright 2026. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 6
Slide 7: Strong Net Product Revenues in Q1 2026
Strong Net Product Revenues in Q1 2026 Net Product Revenues $M • Q1 ‘26 net product revenues of 127.5 $105.4M, +65% vs. prior year 105.4 • Robust sales despite typical 99.2 seasonality and impact from severe 81.5 weather events • GTN stable in the 50s • Expect quarter-over-quarter net sales growth i
Slide 8: Steady TRx Growth for ZORYVE Portfolio
Steady TRx Growth for ZORYVE Portfolio – Reaching ~21,300 Weekly TRx (Rolling 4-Week Basis) 25,000 22,500 20,000 TRx Growth 17,500 Foam 0.30% Cream 0.15% R4 WEEK WEEKLY TRx 15,000 (SebD) Launch (AD) Launch vs. Q4’25 vs. Q1’25 12,500 Cream 0.05% (AD) Launch Q1’26 10,000 Foam 0.30% -6% +43% (PsO) Laun
Slide 9: Entire Topical Market Down in Q1, ZORYVE Outperformed
Entire Topical Market Down in Q1, ZORYVE Outperformed Other Branded Non-Steroidals Market Volume Performance (Q4 ‘25 vs Q1 ‘26) -2% -2% -3% -6% -4% -4% -6% -10% -11% -14% -15% -18% ZORYVE BNST Vit D Analog TCI Antifungal TCS Total Market Relative outperformance drove further ZORYVE share gain in BNS
Slide 10: Continued Investment in Commercial Operations to Drive ZORYVE Inflection
Continued Investment in Commercial Operations to Drive ZORYVE Inflection Completed to Date Future Impact • Anticipate impact on demand beginning Derm sales force Derm expansion launched; early-Q3 Expansion reps now in field • Expansion will further optimize call frequency on mid-decile derm HCPs • A
Slide 11: Speakers & Agenda: R&D Update
Speakers & Agenda R&D Update Patrick Burnett, MD, PhD, FAAD Chief Medical Officer ©Copyright 2026. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 11
Slide 12: INTEGUMENT-INFANT Data Presented in AAD Late-Breaker
INTEGUMENT-INFANT Data Presented in AAD Late-Breaker Roflumilast cream 0.05% improved signs of AD and AD severity through 4 weeks of application 23–month-old White, Asian boy with a history of prior inadequate response, intolerance, or contraindication to TCS 100 vIGA-AD vIGA-AD 0/1 IGA-Scalp EASI-7
Slide 13: INTEGUMENT-INFANT Reinforces ZORYVE's Rapid Impact on Itch
INTEGUMENT-INFANT Reinforces ZORYVE’s Rapid Impact on Itch in AD Patients, to be Further Defined in INTEGUMENT-ITCH Trial INTEGUMENT-1/2 INTEGUMENT-INFANT Change From Baseline in Daily WI-NRS Score a Dynamic Pruritus Score-25b 100 Roflumilast Cream 0.15% (n=884) Vehicle (n=453) 0 Change From Baselin
Slide 14: Our Label Expansion Efforts Aim to Progress ZORYVE
Our Label Expansion Efforts Aim to Progress ZORYVE for the Treatment of Pediatric Patients Adult Pediatric Infant ZORYVE Plaque Psoriasis Ages 6+ Cream 0.3% PDUFA 6/29/26 2-5 yr. ZORYVE Scalp and Body PsO Ages 12+ Foam 0.3% MUSE Trial Fully Enrolled 2-11yr. ZORYVE Atopic Dermatitis Ages 6+; 2-5 Crea
Slide 15: ARQ-234 Mechanism of Action
ARQ-234 Mechanism of Action Checkpoint Agonism Our Target: The CD200 Axis • CD200 and its receptor CD200R are membrane glycoproteins containing two Ig-like domains • CD200 axis plays a role in both innate and adaptive immune cells T and B cells • CD200 is widely expressed on tissues; its only (human
Slide 16: Near-Term Clinical Catalysts
Near-Term Clinical Catalysts Near-Term Clinical Catalysts CLINICAL AND REGULATORY DEVELOPMENTS Topline data for ZORYVE cream 0.05% in infants Atopic dermatitis Q1 2026 Begin enrollment of Phase 1 trial of ARQ-234 Atopic dermatitis Q1 2026 Submit sNDA for ZORYVE cream 0.05% in infants Atopic dermatit
Slide 17: Growing Dialogue on Steroid Stewardship
Growing Dialogue on Steroid Stewardship “Advanced topical nonsteroidal therapies are preferred for long-term management of atopic dermatitis over topical corticosteroids because nonsteroidal therapies avoid corticosteroid-associated adverse events” - Consensus Statements from an Expert Panel ©Copyri
Slide 18: Speakers & Agenda: Financial Results
Speakers & Agenda Financial Results Latha Vairavan Chief Financial Officer ©Copyright 2026. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 18
Slide 19: Q1 2026 Financial Results
Q1 2026 Financial Results GAAP Reported $ Millions, Except Per Share Amounts Q1 2026 Q1 2025 YoY Change Q4 2025 QoQ Change Product Revenues, Net 105.4 63.8 41.6 127.5 (22.1) Other Revenues 0.0 2.0 (2.0) 2.0 (2.0) Total Revenues 105.4 65.8 39.6 129.5 (24.1) Cost of Sales 9.8 8.8 1.0 11.7 (1.9) R&D Ex
Slide 20: Strong Cash Position Through Q1 2026
Strong Cash Position Through Q1 2026 In Millions GAAP Reported Cash Flow & Balance Sheet Data Q1 2026 Cash, Cash Equivalents, and Marketable securities $224.3 Net cash generated in operating activities $2.2 Long-term debt, net $101.5 Weighted average diluted shares outstanding 129.4 Figures may not
Slide 21: Investment in 2026 to Drive ZORYVE Inflection
Investment in 2026 to Drive ZORYVE Inflection with Operating Leverage to Expand in 2027 and Beyond Early Launch Current 2027 and Beyond OPEX SALES OPEX SALES SALES OPEX Cash flow Cash flow Cash flow ©Copyright 2026. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 21
Slide 22: Q&A
Q&A Frank Watanabe Todd Edwards Patrick Burnett, Latha Vairavan President & CEO Chief Commercial MD, PhD, FAAD Chief Financial Officer Chief Medical Officer Officer ©Copyright 2026. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 22
Arcutis Biotherapeutics — Q1 2026 Earnings Presentation on 6ix